Flagler Health has raised $50 million in Series B funding to scale its AI-native platform for musculoskeletal healthcare. Bessemer Venture Partners led the round, with participation from SignalFire, Alumni Ventures, Streamlined, 186 Ventures, Proof VC, Tribeca Ventures, and Offscript. The financing brings the company's total funding to $63 million. The platform integrates with existing electronic medical records and workflows to automate administrative tasks across patient triage, care management, billing, and communications. Founded by former clinic operators, Flagler now serves thousands of providers across 36 states. The company reports its system generates an average of $275,000 in additional annual revenue per provider, whilst 85% of patients report improvements in pain, mood, sleep, or mobility. Musculoskeletal conditions affect over half of US adults and account for more than $400 billion in annual healthcare spending.

Australian medical robotics company Vexev has raised $6 million to advance FDA clearance and US commercialisation of VxWave, its AI-powered robotic ultrasound platform for vascular imaging. The funding brings total investment to $19 million. VxWave combines robotics, artificial intelligence and ultrasound to automate vascular imaging, initially targeting dialysis vascular access monitoring. A recent multi-site clinical study with US Renal Care demonstrated a 94% scanning success rate when operated by non-specialist staff. The round included existing investors Blackbird Ventures, Neotribe Ventures, Startmate and Horizon, alongside new backers TreeArc Investment Group, TEN13, Bioshore Ventures and Alumni Ventures. Funds will support regulatory activities, manufacturing scale-up and commercialisation. Vexev plans to expand the platform beyond dialysis into cardiovascular and peripheral artery disease applications. VxWave remains investigational and awaits FDA clearance for commercial sale.